MDM2 is one of the target genes of the tumor-specific transcription factor p53. It encodes a nuclear phosphoprotein that can bind to and block transactivation of the tumor protein p53 as part of an autoregulatory feedback loop. In the case of overexpression, this gene may cause excessive activation of the tumor protein p53, reducing its function as a tumor suppressor. 

The protein is characterized by E3 Ubiquitin Ligase activity which targets the tumor protein p53 to inhibit proteasomal degradation. The protein also influences cells, cell cycles, apoptosis and tumorigenesis by interfacing with other proteins such as the retinoblastoma-1 protein and the ribosomal protein L5. You can know more about MDM2 antibodies online via https://www.bosterbio.com/anti-mdm2-antibody-pa1378-1-boster.html.

Over 40 different variants of alternatively spliced transcripts have been identified from normal and tumor tissues. MDM2 Antibody (SMP14) is an extremely high-quality monoclonal MDM2 antibody (also known as HdmX antigen and HDM2 antibody) that is suitable for the detection of MDM2 protein, which is of mouse, rat, and human origin. 

MDM2 Antibody (SMP14) is available in both the non-conjugated anti MDM2 antibody and also different conjugated versions of the anti-MDM2 antibody. These include PE, HRP, agarose, FITC and multiple Alexa Fluor (r) conjugates. MDM is also known as murine double minutes-2 was initially discovered as an oncogene in the murine transform system. 

The MDM2 protein is able to bind P53 and inhibit the p53-mediated activation that cotransfected reporter constructs. It is found in a large proportion of human Sarcomas that contain wild-type p53, and tumor cells that express MDM2 may be tolerant of the high levels of p53 expression.